Navigation Links
PAREXEL Reports Preliminary Second Quarter Results
Date:1/12/2009

/p>

PAREXEL does not foresee any restructuring charges or layoffs related to this event. PAREXEL plans to report financial results for the second quarter on January 26, 2009.

Josef von Rickenbach, Chairman and Chief Executive Officer of PAREXEL stated, "We have worked with this client for the past eighteen months, and have been running a large global Phase III clinical trial without incident since September 2007. The client appeared to be adequately funded, had been paying their bills, and indicated to PAREXEL that it had secured venture-backed financing to cover its commitments. However, their financing syndicate unraveled as a result of the global financial crisis, and they were unable to close a planned financing round under their committed capital agreements."

Mr. von Rickenbach continued, "We have conducted a thorough review of the projects/clients in PAREXEL's backlog and receivables, and based upon this review, we believe we do not have any material exposures of a similar nature with other small biopharma clients. Had it not been for the short-term disruption from this client, we believe that the results of the second quarter would have met or exceeded expectations. On the new business front, we are pleased with the level of wins we achieved in the second quarter, and expect to report a net book-to-bill ratio of approximately 1.2. The demand for our services remains strong, and we continue to be positive with regard to the future prospects for the business."

About the Company

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREX
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. PAREXEL International to Present at Bank of America 2008 Smid Cap Conference
2. PAREXEL International to Present at Robert W. Bairds 2008 Growth Stock Conference
3. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
4. PAREXEL International to Present at NASDAQ OMX 22nd Investor Program
5. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
6. Haemacure Reports Third Quarter 2007 Results
7. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
8. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
9. MDS Reports Third Quarter 2007 Results
10. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
11. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... Hologic, Inc.,(Nasdaq: HOLX ) announced today that ... that the pre-market application for,Adiana(R) Permanent Contraception for ... by a vote of 10 to 3., ... traditionally follows the,recommendations of its advisory panels. The ...
... now ensnaring,some of the nations leading retailers, a ... Target, Safeway, and Wild Oats of consumer fraud,for ... in federal courts in Seattle, Denver, and in,Minneapolis, ... class action,lawsuits against Aurora Dairy Corporation, based in ...
... Speaker Nancy Pelosi,issued the following statement on the report ... which found widespread use,of steroids and other illegal substances ... a troubling story of how many of our,children,s heroes ... our national,pastime by using steroids and other illegal substances., ...
... cite concerns that consumers wouldn,t use the cholesterol-lowering drug safely ... time in seven years, U.S. Food and Drug Administration advisers ... the cholesterol-lowering drug Mevacor available over the counter. , In ... advisers said Thursday that it would be too complicated for ...
... IRVING, Texas, Dec. 13 Allarae Healthcare,Inc. (Pink Sheets: ... with Intellect, Inc. to sell their entire product line ... broad range,of personal health testing kits, several already FDA ... kits are ready for market but have,not yet been ...
... Corporation,(Nasdaq: RGEN ) announced today that Dr. ... Board of Directors. Dr. Henry is a highly ... the,development of therapeutics for disorders affecting the Central ... an executive with Earl,s industry,knowledge and drug development ...
Cached Medicine News:Health News:FDA Advisory Panel Finds Hologic's Adiana(R) Permanent Contraception Approvable 2Health News:FDA Advisory Panel Finds Hologic's Adiana(R) Permanent Contraception Approvable 3Health News:FDA Advisory Panel Finds Hologic's Adiana(R) Permanent Contraception Approvable 4Health News:Nation's Largest Retailers Accused of Organic Fraud 2Health News:FDA Advisers Reject Over-the-Counter Statin 2Health News:FDA Advisers Reject Over-the-Counter Statin 3Health News:FDA Advisers Reject Over-the-Counter Statin 4Health News:Allarae Healthcare Inc. Announces Signing of Distribution Agreement With Intellect Inc. 2Health News:Repligen Elects Earl Henry, M.D. to the Board of Directors 2Health News:Repligen Elects Earl Henry, M.D. to the Board of Directors 3
(Date:1/15/2014)... , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ... has fueled rapid growth of these markets. ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ... $2.92 per share, net to the seller in cash, ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ... composition, including reductions in body fat content and ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... 10, 2011 Unity Management Group, Inc. (PINKSHEETS: ... Resource Company specializing in Physician and Hospital Practice ... with Pharmacy Instrumentation, Calibration, Data Acquisition, and Equipment ... announce today that (MCC) Metropolitan Computing Corporation has ...
... The U.S. Food and Drug Administration today cleared the ... perform a positron emission tomography scan, commonly known as ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... organs and tissues inside the body are actually functioning ...
Cached Medicine Technology:Unity Management Group, MCC Announce Increased Contracts and Major Installations at US and South American Pharmaceutical Companies 2Unity Management Group, MCC Announce Increased Contracts and Major Installations at US and South American Pharmaceutical Companies 3FDA Clears New System to Perform Simultaneous PET, MRI Scans 2FDA Clears New System to Perform Simultaneous PET, MRI Scans 3
Flexilog custom medical carts are configured to suite the requirements of FLEXILOG motility system users. With locking wheels and storage drawers, our carts are suitable for any care provider in any ...
... Calibration kit for convenient pH catheter calibration., ... to any procedure. The Alpine Calibration kit ... distilled water for your convenience. Simply cut ... your catheters to soak. No measuring or pouring! ...
Bravo Tubing/Filter Supplies (Ten tubing sets, ten filters)...
Bravo pH capsule with delivery system....
Medicine Products: